Latest News
Get real-time updates on the latest news and developments in the pharmaceutical world. Stay informed about new drug launches, research findings, regulatory changes, and industry updates. Explore a wide range of topics and stay connected with the rapidly evolving world of pharma.
FDA Grants Approval: Reblozyl’s Triumph Ushers in a New Dawn for Anemia Treatment
Bristol Myers Squibb has ushered in a breakthrough in the realm of medical advancements, announcing the FDA’s seal of approval ...
Navigating Peaks and Valleys: Novocure’s Tumor Treating Fields Unveil Divergent Outcomes
In the complex realm of medical breakthroughs, the journey from triumph to setback can be as unpredictable as it is ...
Bayer Advances Parkinson’s Cell Therapy to Phase 2 Trial
A new horizon gleams for Bayer’s quest to conquer Parkinson’s disease through advanced cell therapy. In a significant revelation, the ...
Legal Engagements Amid Scientific Advancements: Alnylam’s Ongoing Interplay with Moderna
In the intricate choreography of the biopharmaceutical world, where innovation and intellectual property intertwine, a dramatic legal ballet unfolds. Alnylam, ...
FTC’s Legal Pas de Deux: A Pause in the Amgen-Horizon Acquisition
In the world of corporate clashes and strategic maneuvers, a legal ballet is unfolding, with the Federal Trade Commission (FTC) ...
Abcam’s Harmonious Acquisition by Danaher Shaping the Future of Antibody Research
In the realm where science meets commerce, a symphony of strategy and innovation is playing out. Just two months since ...
A Symphony of Change: Moderna’s Second Serve at the US Open Celebrates Arthur Ashe’s Legacy
After paying homage to the iconic Billie Jean King in their previous year’s advertisement, this year’s rendition shines a spotlight ...
Legal Skirmishes Erupt as AstraZeneca Delves into Battle Over Drug Pricing Reforms with IRA
As the clock ticks down to the eagerly awaited unveiling of the Centers for Medicare and Medicaid Services’ (CMS) list ...
Novo Nordisk’s Semaglutide Triumphs Again: A Heartfelt Victory in the Battle Against Heart Failure
In a remarkable turn of events, the pharmaceutical landscape witnesses Novo Nordisk’s semaglutide, a true star in its arsenal, claiming ...
Setbacks Continue: Merck and Eisai’s Ambitious Combo of Keytruda-Lenvima Stumble in Head and Neck Cancer Battle
In a somber development for the pharmaceutical world, Merck and Eisai find themselves facing yet another roadblock on their quest ...
FDA Approves Novartis’ Tyruko: Revolutionizing MS Treatment Landscape Amidst Legal Drama
Stepping onto the stage with a flourish, Novartis has secured a resounding victory against Biogen in the realm of pharmaceutical ...
Merck’s Bold Bet: 6-Year Study on Oral PCSK9 Inhibitor Dominates Phase 3 Program
In the ever-evolving landscape of pharmaceutical breakthroughs, Merck & Co. has set its sights on a pioneering endeavor that could ...
EC Approves Pfizer’s Abrysvo, Only RSV vaccine in EU for adults and infants
Pfizer has just received approval from the European Commission (EC) for its groundbreaking vaccine, Abrysvo. This vaccine, targeting the respiratory ...
Exelixis Celebrates Early End to Cabometyx Trial for Neuroendocrine Tumors due to Remarkable Efficacy
Exelixis, a drug developer, recently halted a cancer trial involving Cabometyx, their tyrosine kinase inhibitor, due to an overwhelming display ...
Akebia plans to resubmit vadadustat to FDA after rejection
After facing significant setbacks, including disappointment, a partnership setback, and an FDA dispute, Akebia Therapeutics has regrouped and is poised ...
Roche’s Latest KRAS Data Shows Promise Against Amgen and Mirati, Yet Verdict Remains Uncertain
Roche has presented compelling new data showcasing its KRAS inhibitor, divarasib, as a potential contender against rivals Amgen and Mirati. ...
Ferring Strikes $500M Agreement with Royalty Pharma for Innovative Bladder Cancer Gene Therapy
Royalty Pharma has carved a distinctive niche in the pharmaceutical landscape, specializing in identifying innovative products both pre- and post-approval, ...
Dräger Faces FDA Class I Recall on Carina Ventilators Due to Contaminant Concerns
Dräger, a German medical device manufacturer, is grappling with its fourth Class I recall by the FDA this year, this ...
Pfizer’s Approach to GBS Vaccine Approval Hinges on Immunogenicity Study
Amid the complexities of conducting an efficacy study for a group B streptococcus (GBS) vaccine, Pfizer’s lead vaccine executive is ...
Amgen challenges FTC’s bid to block $28B Horizon deal
Amid the ongoing legal battle with the Federal Trade Commission (FTC) over its $28 billion acquisition of Horizon Therapeutics, Amgen ...
FDA Advisors Favor Otsuka’s ReCor and Express Reservations on Medtronic’s Renal Denervation Therapies
During a two-day-long FDA meeting, a panel of advisors deliberated over competing proposals for novel renal denervation therapies, ultimately granting ...
Horizon Surpasses Roche in Rare Disease Reputation, While Pfizer’s Standing Declines
Horizon Therapeutics continues to collect accolades as it progresses toward its acquisition, with rare disease organizations now recognizing its excellence. ...
Cellares Announces $255M Investment Round with Bristol Myers Squibb Among Key Investors
Cellares, a pioneering cell therapy manufacturer based in South San Francisco, has introduced a unique concept in the industry with ...
Roche Unveils Interim TIGIT Overall Survival Data Following Unintended Release, Triggering Surge in Stocks
An unexpected revelation has provided the world with a sneak peek into Roche’s highly anticipated TIGIT data. Roche, which had ...
Following $1.7B Opioid Settlement, Mallinckrodt Prepares for Second Round of Bankruptcy Proceedings
In a recent development, Mallinckrodt has formally announced its decision to initiate another round of bankruptcy proceedings, marking its second ...
Agenus Shifts Focus to CTLA-4/PD-1 Combo Treatment, Implementing Layoffs and Pipeline Refinement
Agenus, an immuno-oncology firm, is reshaping its strategy to prioritize its CTLA-4/PD-1 combo treatment while temporarily redirecting its unpartnered programs. ...
Novartis Announces New Round of Layoffs at US Headquarters Following Earlier Job Cuts
Novartis, a Swiss pharmaceutical giant, is set to undergo another round of job cuts at its U.S. headquarters in East ...
Boehringer Ingelheim Enters Legal Fray Against Inflation Reduction Act, Citing Constitutional Concerns
The legal battle surrounding the Inflation Reduction Act (IRA) has intensified as pharmaceutical giant Boehringer Ingelheim joins the ranks of ...
FDA Rebukes Exeltis Over Misleading Social Media Post for Birth Control Pill Slynd
Exeltis, a pharmaceutical company, has come under sharp criticism from the FDA for a sponsored social media post promoting its ...
Novo Nordisk Turns to Thermo Fisher for Production Aid with Obesity Drug Wegovy Amid Catalent Challenges
Novo Nordisk Struggles to Keep Up with High Demand for Wegovy, Enlists Thermo Fisher to Boost Production Amid soaring demand ...
